Related by context. All words. (Click for frequent words.) 69 TKM ApoB 68 Fibrillex TM 68 ularitide 68 CK # 67 nalbuphine ER 67 MYDICAR ® 67 Androxal TM 67 Dextofisopam 66 cannabinor 66 cardiac contractility 66 ancrod 66 UVIDEM 66 PEG PAL 66 R#/MEM # 65 catheter occlusion 65 elotuzumab 65 metaglidasen 65 ALN TTR# 65 MAXY alpha 65 Phenoptin 65 TNF antagonist 65 urocortin 2 65 synthetic retinoid 65 Behcet uveitis 65 ARIKACE ™ 64 opioid induced bowel dysfunction 64 riociguat 64 Dacogen injection 64 Prestara 64 Exelixis compounds 64 AZX# 64 Phase IIB 64 oxymorphone ER 64 GGF2 64 Viprinex TM 64 TELINTRA 64 Chrysalin 64 bardoxolone 64 torsemide ER 64 Plicera 64 evaluating CK # 64 nonclinical studies 64 ATL# [001] 64 celgosivir 64 EGS# 64 MAXY G# 64 AzaSite Plus 64 phase IIb clinical 64 atacicept 64 sitaxsentan 63 Desmoteplase 63 XP# XP# 63 GSK# [001] 63 AERx iDMS 63 squalamine 63 RAPTIVA R 63 ELACYT 63 RSD# oral 63 Cloretazine R VNP#M 63 lomitapide 63 methylnaltrexone 63 alagebrium 63 teduglutide 63 Thalomid ® 63 PRT# 63 INCB# [001] 63 JAK inhibitor 63 dimebon 63 RSD# iv 63 bicifadine 63 INTEGRILIN 63 vidofludimus 63 CORLUX CORT # 63 AZASITE 63 novel VDA molecule 63 SparVax TM 63 C1 INH 63 TBC# 63 metastatic HRPC 63 forodesine 63 ISIS # 62 Phase IIa clinical trials 62 Phase #b/#a trial 62 GAMMAGARD 62 clinical pharmacology studies 62 Bicifadine 62 CTAP# Capsules 62 paclitaxel eluting stents 62 #ME# 62 MAXY VII 62 selective androgen receptor modulator 62 dexanabinol 62 interferon gamma 1b 62 MYDICAR 62 EP #R 62 alvespimycin 62 EDEMA3 trial 62 Cleviprex TM clevidipine 62 Actimmune ® 62 Phase #b/#a 62 NLX P# 62 phase IIa clinical 62 Fx #A 62 Bezielle 62 MERLIN TIMI 62 PS# [001] 62 HCD# [002] 62 systemically administered 62 Actimmune R 62 pharmacokinetic characteristics 62 GED aPC 62 vosaroxin 62 PSMA ADC 62 CD# CEA 62 custirsen 62 Symadex 62 XL# XL# XL# XL# 62 Virulizin ® 62 Azedra TM 62 Increlex R 62 OvaRex ® MAb 62 mGluR5 NAM 62 Triolex 62 ATACAND 62 mecarbil 62 PREOS R 62 YONDELIS 62 Phase IIa trials 62 Xanafide 62 PROMACTA 62 Azedra 62 cilengitide 62 dacetuzumab 62 ORENCIA R 62 HepeX B 62 Urocortin 2 62 aplindore 62 MGd 62 PDE# inhibitors 62 hyperphenylalaninemia HPA due 61 CCX# 61 NEUMUNE 61 CORT # 61 CIMZIA TM certolizumab pegol 61 Octreolin 61 diarrhea predominant irritable 61 ocrelizumab 61 non constipating irritable 61 antiarrhythmic drug 61 danoprevir 61 Tamibarotene 61 Archexin 61 Sulonex 61 SNT MC# 61 fibrotic disease 61 ATL# [002] 61 SILENOR TM 61 Solazed 61 Cethrin 61 Zerenex 61 SYMMETRY trial 61 EndoTAG TM -1 61 Neuradiab 61 cinacalcet HCl 61 Oxypurinol 61 GLP1 agonist 61 TRIOLEX 61 CIMZIA ™ 61 OHR/AVR# 61 6R BH4 61 Adentri 61 Relivar 61 IMiDs 61 E1 INT TM 61 R#/MEM 61 alvimopan 61 diabetic neuropathic pain 61 rNAPc2 61 oral prodrug 61 rhIGF-I/rhIGFBP-3 61 senicapoc 61 ALN PCS 61 UPLYSO 61 Posiphen 61 Virulizin R 61 ELND# 61 BrachySil TM 61 GRNCM1 61 plasma pharmacokinetics 61 ICA # 61 INTEGRILIN ® 61 otelixizumab 61 tezampanel 61 PEG INTRON 61 RNAi therapeutic targeting PCSK9 61 Phase Ib study 61 Ecallantide 61 Vernakalant 61 Panzem R 61 EVIZON 61 RLY# 61 AQ4N 61 ENMD # 61 refractory angina 61 Aurexis 61 Phase 2a trial 61 tolvaptan 61 unstable angina pectoris 61 APTIVUS r 61 talactoferrin 61 Traficet EN 61 tafamidis 61 CEQ# 61 dirucotide 61 oral talactoferrin 61 Tasimelteon 61 neovascular 61 neurogenic orthostatic hypotension 61 Cetrorelix 61 IV APAP 61 maribavir 61 SinuNase TM 61 Sulonex TM 61 pharmacodynamic 61 diabetic nephropathy 61 darapladib 61 refractory gout 61 PRIMO CABG2 61 Telintra 61 angiographic outcomes 61 mertansine 61 bevasiranib 61 Pyridorin 61 VIAject ™ 61 including eniluracil ADH 61 valopicitabine 61 INTERCEPT platelets 61 torezolid phosphate 60 eprotirome 60 Pharmacokinetic parameters 60 Factor VIIa 60 serum phosphorous 60 tramiprosate ALZHEMED TM 60 tanespimycin 60 Proellex TM 60 Aryplase 60 bafetinib 60 Trofex 60 budesonide foam 60 liposomal formulation 60 Ventavis ® 60 HGS ETR2 60 investigational monoclonal antibody 60 A1PI 60 ostarine 60 preclinical efficacy 60 Phase IIb clinical trials 60 proteasome inhibitor 60 Apoptone 60 volociximab 60 Synavive 60 recurrent glioblastoma multiforme 60 relapsed MM 60 Panzem R NCD 60 MNTX 60 Protexia ® 60 PLK1 SNALP 60 subcutaneous RELISTOR 60 pegaptanib 60 EXJADE 60 PRX # 60 PI3K/Akt pathway inhibitor 60 hypoparathyroidism 60 posaconazole 60 NOX E# 60 Mipomersen 60 Squalamine 60 dose escalation phase 60 pradefovir 60 DDP# 60 INCB# [002] 60 rindopepimut 60 ataluren 60 pegloticase 60 low dose cytarabine 60 eniluracil 60 Asentar 60 antithrombotic 60 AEG# 60 CINTREDEKIN BESUDOTOX 60 Phase 2a clinical trials 60 Evoltra ® 60 either acutely decompensated 60 VIAtab TM 60 Phenserine 60 pharmacodynamic PD 60 IV Busulfex 60 terlipressin 60 ATryn ® 60 Civacir 60 GATTEX TM 60 CK # administered 60 ARCALYST ® 60 Aloxi injection 60 QT QTc 60 THALOMID 60 Trofex TM 60 davunetide intranasal AL 60 Protexia R 60 lintuzumab SGN 60 teriflunomide 60 Cinryze ™ 60 orally administered inhibitor 60 GFT# 60 CD# antibody [001] 60 erythropoietic 60 Amrubicin 60 DPP4 60 pharmacokinetic PK 60 HuLuc# 60 acetonide FA 60 immunomodulation 60 PXD# 60 BLA submission 60 Tavocept 60 Entereg R 60 NP2 Enkephalin 60 antiarrhythmic 60 BAY #-# 60 olmesartan 60 rFVIIa 60 SEPET TM 60 vernakalant hydrochloride 60 trastuzumab DM1 T DM1 60 dosing cohort 60 TRX1 60 TREANDA 60 Androxal ® 60 urate lowering 60 tramiprosate Alzhemed TM 60 TH# [003] 60 AERx ® 60 QLT# 60 Increlex ® 60 Phase 1a clinical 60 Spheramine 60 antiangiogenic 60 cMET 60 Stimuvax R 60 retinal vein occlusion induced 60 rhIGFBP 3 60 Phase IIIb clinical 60 octreotide implant 60 RSD# 60 Urocidin TM 60 Cellegesic 60 cMET inhibitor 60 INS# [001] 60 Microplasmin 60 PSN# [002] 60 DCCR 60 Spiegelmer ® 60 Azedra ™ 60 VEGF Trap 59 acute mania 59 Alzhemed TM 59 RenaZorb TM 59 hoFH 59 Lixivaptan 59 DOS# 59 pafuramidine 59 JAK inhibitors 59 alemtuzumab MS 59 cardiac repolarization 59 INCB# [003] 59 PRTX 59 PrevOnco ™ 59 MAGE A3 ASCI 59 RAPTIVA 59 EVIZON TM squalamine lactate 59 MoxDuo TM IR 59 Prodarsan ® 59 OXi# 59 drug ISA# 59 HuMax CD4 59 CYPHER R Sirolimus eluting 59 glufosfamide 59 GALNS 59 subcutaneously administered 59 R sorafenib tablets 59 linear pharmacokinetics 59 pharmacodynamic effects 59 FOSRENOL ® 59 SERCA2a 59 QNEXA 59 schizophrenia CIAS 59 trastuzumab emtansine T DM1 59 calcineurin inhibitor 59 selective GR 59 FOLOTYN ® 59 BCX# 59 PHX# 59 SILENOR ™ 59 Ostarine 59 VAPRISOL 59 cobiprostone 59 ambrisentan 59 midstage trials 59 haematologic 59 candesartan cilexetil 59 deferiprone 59 lanthanum carbonate 59 clazosentan 59 CB2 selective receptor agonist 59 dirucotide MBP# 59 Solazed TM 59 PDE4 inhibitor 59 r hGH 59 CIMZIA TM 59 CINQUIL 59 Increlex TM 59 hypogonadal men 59 RhuDex ® 59 Epanova 59 HoFH 59 symptomatic neurogenic orthostatic hypotension 59 Somatuline Depot 59 treprostinil 59 prokinetic agent 59 eszopiclone 59 thorough QT 59 Solulin 59 Lisofylline LSF 59 Viprinex 59 phase IIb 59 DXL# 59 dyskinesia PD LID 59 MIST II 59 tramiprosate 59 dose cohorts 59 intravenous iv 59 ONTAK 59 lixivaptan 59 IPLEX 59 NGX# 59 EVIZON TM 59 eculizumab 59 velafermin 59 ALN RSV# 59 vernakalant oral 59 MEK inhibitor 59 XmAb# 59 Study GL# 59 regadenoson 59 daptomycin 59 placebo controlled clinical 59 decitabine 59 alteplase 59 BYETTA exenatide injection 59 DEB# 59 octreotide acetate 59 desvenlafaxine succinate 59 HDL Selective Delipidation 59 2 methoxyestradiol 59 Onrigin TM 59 Prodarsan R 59 GSK # 59 NeuroSTAT ® 59 dose cohort 59 everolimus eluting stents 59 lumiliximab 59 Somatuline R Depot 59 DexaSite 59 ThGRF 59 Retisert 59 incyclinide 59 lesinurad 59 preclinical 59 Xcytrin R 59 SILENOR 59 relapsed multiple myeloma 59 baminercept 59 Anturol TM 59 cytopenias 59 PREOS 59 huC# DM4 59 TÎ ² 4 59 avosentan 59 peginesatide 59 zileuton IV 59 oral rivaroxaban 59 Phase IIa clinical 59 oxcarbazepine 59 myoblast therapy 59 POSIDUR TM 59 multicenter Phase II 59 inhaled treprostinil 59 Aviptadil 59 confirmatory Phase III 59 Proquin XR 59 MyoCell SDF 1 59 selective modulator 59 eosinophilic asthma 59 cerebral ischemia 59 CytoFabTM 59 IV NSCLC 59 XL# anticancer compounds 59 mGluR2 NAM 59 GATTEX ™ 59 morphometric vertebral fractures 59 dosage regimens 59 LNP formulations 59 teplizumab 59 IFN α 59 pharmacodynamic parameters 59 alkylating agent 59 AAG geldanamycin analog 59 INTEGRILIN R eptifibatide Injection 59 HCV protease inhibitors 59 MAP# 59 Cinryze TM 59 SIRT1 activators 59 phase 2a 59 somatostatin analog 59 XOMA 3AB 59 Zemplar Capsules 59 Medidur TM 59 ABILIFY ® 59 Maxy G# 59 immunomodulatory 59 VELCADE melphalan 59 rhMBL 59 TRO# 59 Generx TM 59 pitavastatin 59 fostamatinib 59 dose escalation Phase 59 IPLEX TM 59 Shigamabs ® 59 HQK 59 GnRH agonist 59 DR Cysteamine 59 PRIMO CABG 59 faropenem 59 midstage clinical 59 SomatoKine 59 kidney urologic 59 EDARBI 59 tesmilifene 58 CaPre TM 58 bexarotene 58 TNF alpha antagonist 58 HspE7 58 uric acid lowering 58 Onalta 58 PNP inhibitor 58 inotropes 58 punctal plug drug 58 IPL# 58 Candesartan 58 REPLAGAL 58 TRIOLEX HE# APOPTONE HE# 58 Chemophase 58 Canvaxin TM 58 sodium thiosulfate STS 58 Tß4 58 clevudine 58 ACE inhibitor ramipril 58 Amigal 58 alpha#beta# integrin 58 anti amnesic 58 MTP inhibitor 58 blood clot dissolver 58 sulodexide 58 lupus nephritis 58 LymphoStat B TM 58 mg kg dose 58 fosbretabulin 58 ascending dose 58 myeloproliferative diseases 58 LEUKINE 58 SinuNase 58 PAOD 58 Specifid 58 DU #b 58 AGGRASTAT ® 58 ELADUR 58 SonoLysis 58 oxaliplatin Eloxatin 58 hormone LHRH antagonist 58 Cytokinetics specified 58 serum phosphate 58 PEGylated 58 muraglitazar 58 Exherin TM 58 CINOD 58 O PPDS 58 Losartan 58 glucokinase activator 58 ischemic cardiomyopathy 58 pexelizumab 58 induced macular edema 58 punctal plug 58 exocrine pancreatic insufficiency 58 postmenopausal osteoporotic women 58 ProSavin 58 LEP ETU 58 GEM OS2 58 Alvesco R 58 LB# [003] 58 ATL/TV# 58 Androxal 58 cancer neuroendocrine tumor 58 Triapine R 58 edifoligide 58 acute decompensated heart 58 Zevalin consolidation 58 class mGluR5 inhibitor 58 iSONEP 58 Tasigna prolongs 58 serum phosphate levels 58 Omigard 58 TACI Ig 58 Thrombin 58 weekly subcutaneous injections 58 PhosLo 58 Nanobody 58 hepatic enzyme 58 thymalfasin 58 CCX# B 58 TRANSDUR Sufentanil 58 brivaracetam 58 receptor inhibitor 58 phase IIa 58 ORMD 58 elagolix 58 herpetic keratitis 58 HCV RESPOND 2 58 Pivotal Phase III 58 BENICAR HCT 58 AP# [003] 58 viral kinetics 58 intranasal formulation 58 Pimavanserin 58 Sym# 58 Riquent 58 Aganocide TM 58 lupus renal disease 58 left ventricular systolic 58 favorable pharmacokinetic profile 58 inhaled formulation 58 Catena ® 58 Zavesca ® 58 PDE4 inhibitors 58 inflammatory autoimmune diseases 58 Soliris TM eculizumab 58 renal toxicity 58 AZOR 58 thienopyridine 58 Natalizumab 58 RITUXAN 58 DP b# 58 certolizumab 58 metabolic parameters 58 phase IIb trial 58 non nucleoside HCV 58 TELCYTA 58 Neo Kidney Augment 58 tesetaxel 58 gallium containing 58 epoprostenol 58 Neulasta ® 58 intracranial hemorrhage ICH 58 eprodisate Fibrillex TM 58 EOquin TM 58 Vaxfectin R 58 statistically significant efficacy 58 LymphoStat B Phase 58 intracoronary 58 Stedivaze 58 pomalidomide 58 CYT# potent vascular disrupting 58 Cloretazine 58 NovoSeven ® 58 Erythropoietic therapies may 58 unresectable HCC 58 Nicole Onetto MD 58 elacytarabine 58 Randomized Phase 58 left ventricular dysfunction 58 Allovectin 7 R 58 azacitidine 58 Soliris eculizumab 58 Preclinical studies suggest 58 HIV HCV coinfected 58 oral calcitonin 58 XL# XL# 58 Forodesine HCl 58 ZYFLO 58 Phase #/#a 58 confirmatory clinical 58 novel synthetic PEGylated 58 pharmacokinetic interactions 58 denufosol 58 product platforms AZX# 58 secondary hyperparathyroidism 58 omega interferon 58 Acute Radiation Syndrome ARS 58 Genentech Rituxan 58 NYHA Class II 58 ALN HPN 58 serum calcium levels 58 oral methylnaltrexone 58 Allovectin 7 58 goserelin 58 AZD# TC 58 CANCIDAS 58 PD LID 58 Tekamlo 58 aurora kinase 58 antidepressant efficacy 58 Altastaph 58 vilazodone 58 PrevOnco 58 galiximab 58 Veronate 58 ruxolitinib 58 initiate Phase 1b 58 lintuzumab 58 Omacetaxine mepesuccinate 58 serum uric acid sUA 58 dextromethorphan quinidine 58 humanized anti 58 pharmacokinetic studies 58 JUVISTA 58 KNS # 58 PEG Interferon lambda 58 Trizytek 58 AEGR 58 FROVA 58 TRISENOX 58 opioid bowel dysfunction 58 IIIa inhibitor 58 antisense drug 58 intensive lipid lowering 58 postoperative ileus 58 Capesaris 58 BrachySil ™ 58 HeFH 58 NV1FGF 58 Thelin tm 58 tasimelteon 58 raxibacumab 58 NNR Therapeutics 58 Known hypersensitivity 58 orally administered synthetic retinoid 58 PROSTVAC VF 58 IOP lowering 58 vaso occlusive crisis 58 placebo controlled Phase 58 AGGRASTAT R 58 INSPIRE Trial Phase III 58 HuMax EGFr 58 CIP TRAMADOL ER 58 Unit Dose Budesonide 58 intravenous cyclophosphamide 58 Aptivus ® 58 Argatroban 58 Factor IX 58 glycated hemoglobin levels 58 PRECISE trial 58 NEBIDO 58 Nanobody ® 58 CYCLOSET 58 alfimeprase 58 pan HDAC inhibitor 58 trastuzumab Herceptin ® 58 VLTS 58 metformin sulfonylurea 58 Optiquel ™ 58 CB2 selective 58 placebo controlled Phase III 58 Pruvel 58 Zemiva TM 58 Oncaspar 58 Vitaxin 58 preclinical studies 58 prostanoid 58 NAGS deficiency 58 XAGRID 58 gastrointestinal disorders ATI 58 PEG SN# 58 pamidronate 58 Tarceva TM 58 EHT AGN 58 Rescula 58 ACAPODENE 58 LymphoStat B belimumab 58 antiplatelet agent 58 methylnaltrexone bromide 58 intravitreal injection 58 STEDESA 58 NPH insulin 58 RHUCIN 58 Hedgehog antagonist 58 oral FTY# 58 dosing cohorts 58 valopicitabine NM# 58 AeroLEF TM 58 Diamyd ® 58 Syncria 58 GTC recombinant human 58 active comparator 58 acute ischemic stroke 58 chemotherapy induced neutropenia 58 Kyowa Kirin 58 hypercholesterolemic patients 58 DYNEPO 58 cardiac myosin activator omecamtiv 58 LUNESTA TM 58 eprodisate KIACTA TM 58 serum urate 58 Phase 2b study 58 Val HeFT 58 HuMax CD# 58 palonosetron 58 Phase Ib clinical trials 58 plasma kallikrein inhibitor 58 preclinical pharmacokinetic 58 MGCD# [001] 58 PRX# 58 STRIDE PD 58 pharmacodynamic profile 58 Phase 2b trial 58 selective agonists 58 atrial fibrillation budiodarone ATI 58 null responder 58 bezafibrate 58 DITPA 58 menadione 58 Zavesca R 58 LHRH antagonists 58 irbesartan 58 immunomodulatory therapy 57 hypercholesterolemia 57 cleavable linker 57 5 HT2C receptor 57 Hedgehog Pathway Inhibitor 57 ATryn R 57 LUCENTIS 57 XERECEPT R 57 CCR5 mAb 57 investigational humanized monoclonal antibody 57 EOquin 57 ruboxistaurin 57 XL# [003] 57 PROCHYMAL 57 eltrombopag 57 JAK3 57 AGHD 57 inhibitor RG# 57 Kepivance 57 GLPG# 57 retinal vein occlusion 57 SPRIX ® 57 Fentanyl TAIFUN R 57 oxypurinol 57 R lenalidomide 57 tecarfarin 57 neutropenia dehydration dyspnea 57 calcineurin inhibitors 57 MyoCell 57 TOLAMBA 57 AGGRASTAT ® tirofiban hydrochloride 57 ALN VSP 57 DACH platinum 57 Zevalin R Ibritumomab 57 SPRYCEL ® 57 ZADAXIN ® 57 intravenous immunoglobulin IVIg 57 composite endpoint 57 Captisol enabled 57 symptomatic hyponatremia 57 VITAL Trial 57 Brinavess 57 Phase 1b clinical trials 57 AGILECT R 57 ceftazidime 57 ATPace TM 57 Granulocyte Colony Stimulating Factor 57 ZYFLO CR 57 Nexavar sorafenib 57 Oral NKTR 57 ganetespib 57 amrubicin 57 PF # [001] 57 HCV SPRINT 57 Ereska 57 relapsed refractory multiple myeloma 57 salmeterol HFA MDI 57 GRN# 57 ACTEMRA TM 57 sJIA 57 nicotinic alpha 7 57 prostone 57 choroidal vasculopathy 57 Adenoscan 57 tumor lysis syndrome 57 HGS ETR1 57 CRLX# 57 tamibarotene 57 pharmacodynamic profiles 57 TORISEL 57 albinterferon alfa 2b 57 #mg/day [002] 57 GATTEX ® 57 antidepressants fluoxetine 57 catheter occlusion CO 57 TAXUS TM 57 BLA filing 57 CA4P 57 latrepirdine 57 novel histone deacetylase 57 CCR9 antagonist 57 ZYBRESTAT fosbretabulin 57 lenalidomide Revlimid R 57 factor VIIa 57 Naglazyme 57 ZOLINZA 57 Troxatyl 57 refractory CLL 57 Icatibant 57 Cinquil 57 Linjeta TM 57 Frova ® 57 Phase IIa trial 57 Aurora kinase 57 aflibercept 57 insulin detemir 57 Tyrima 57 severe gastroparesis 57 CoFactor 57 IAP inhibitor 57 rilonacept 57 Azixa 57 TREDAPTIVE 57 TYZEKA 57 IL# PE#QQR 57 torcetrapib atorvastatin 57 HGS ETR1 mapatumumab 57 pharmacokinetics pharmacodynamics 57 multicenter Phase III 57 Technosphere Insulin 57 KRN# 57 Perceiva 57 rhFVIIa 57 enoximone 57 Tolvaptan 57 Insulin PH# 57 Multiple Ascending Dose 57 Poly ICLC 57 HDL Mimetic Peptide 57 decompensated liver disease 57 Nasulin 57 adenosine injection 57 RE LY ® 57 OLEPTRO TM 57 ONCONASE R 57 Eligard ® 57 molecular chaperone amplification 57 PC DAC Exendin 57 ABSORB trial 57 antimetabolite 57 azilsartan medoxomil 57 MEND CABG II 57 BXT # 57 rufinamide 57 THR beta agonist 57 carcinoid syndrome 57 Targretin capsules 57 FRDA 57 Virulizin 57 markets Testim ® 57 ARCOXIA 57 demonstrated clinically meaningful 57 opioid analgesia 57 Neulasta R 57 NEVO ™ 57 RNAi therapeutic targeting 57 rhC1INH 57 Miraxion 57 naïve HCV 57 #beta HSD1 57 ASONEP 57 Phase IIb trials 57 MoxDuo IR 57 Insegia 57 BeneFIX 57 ridaforolimus